Brief: Sangamo Therapeutics & Astellas Enter Capsid License Agreement
19/12/2024 07:35
Dec 19 (Reuters) - Sangamo Therapeutics Inc SGMO.O &
Astellas Pharma Inc 4503.T :
* SANGAMO THERAPEUTICS AND ASTELLAS ANNOUNCE CAPSID LICENSE
AGREEMENT TO DELIVER GENOMIC MEDICINES FOR NEUROLOGICAL DISEASES
* SANGAMO THERAPEUTICS INC - ELIGIBLE FOR UP TO $1.3 BILLION
IN
MILESTONE PAYMENTS
* SANGAMO THERAPEUTICS INC - TO RECEIVE $20 MILLION UPFRONT
LICENSE FEE
Source text: ID:nBw8WQ71Ra
Further company coverage: 4503.T
((Reuters.Briefs@thomsonreuters.com))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)